Chemomab Therapeutics LtdNASDAQ:CMMBNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.6200/ 1
- Ask / Lots0.7600/ 1
- Open / Previous Close0.0000 / 0.7000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CMMB |
|---|---|---|
| 09:32 ET | 5051 | 0.649999 |
| 10:10 ET | 950 | 0.624891 |
| 10:19 ET | 100 | 0.6251 |
| 10:21 ET | 100 | 0.6299 |
| 10:30 ET | 4501 | 0.6499 |
| 10:33 ET | 1100 | 0.65 |
| 10:35 ET | 500 | 0.643153 |
| 10:39 ET | 144 | 0.6201 |
| 10:42 ET | 200 | 0.64999 |
| 10:44 ET | 100 | 0.62 |
| 11:00 ET | 348 | 0.620101 |
| 11:33 ET | 406 | 0.649 |
| 11:36 ET | 4234 | 0.65 |
| 11:38 ET | 400 | 0.64 |
| 11:40 ET | 100 | 0.7 |
| 11:54 ET | 100 | 0.66 |
| 12:25 ET | 150 | 0.620001 |
| 12:38 ET | 200 | 0.65999 |
| 01:06 ET | 1400 | 0.66 |
| 01:21 ET | 135 | 0.65 |
| 02:15 ET | 153 | 0.6501 |
| 03:05 ET | 985 | 0.66 |
| 03:14 ET | 126 | 0.65 |
| 03:48 ET | 300 | 0.65 |
| 03:52 ET | 467 | 0.665 |
| 03:57 ET | 300 | 0.674 |
| 03:59 ET | 581 | 0.7 |
Yesterday
Apr 2, 2024
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024, from 7:00AM ET on Tuesday Apr 02, 2024 by Dow Jones
7:00AM ET on Tuesday Apr 02, 2024 by Dow Jones
Mar 25, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Chemomab Therapeutics Ltd | 9.9M | 0.0x | --- |
NuCana PLC | 8.0M | 0.0x | --- |
Weed Inc | 10.0M | -353.3x | --- |
Galera Therapeutics Inc | 10.1M | -0.1x | --- |
Akari Therapeutics PLC | 9.6M | -0.6x | --- |
National Graphite Corp | 10.5M | -3.1x | --- |
Company Information
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Contact Information
- Headquarters
- Kiryat Atidim, Building 7TEL AVIV-YAFO, Israel 6158002
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Nissim Darvish
- Chief Executive Officer, Director
- Adi Mor
- Chief Financial Officer
- Sigal Fattal
- Chief Medical Officer, Vice President - Drug Development
- Matthew Frankel
- Independent Director
- Neil Cohen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $9.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 14.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.39 |
EPS | $-42.37 |
Book Value | $23.93 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
